Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 233

1.

Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns.

Kreyenbuhl JA, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Psychiatr Serv. 2007 Apr;58(4):489-95.

PMID:
17412850
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Long-term combination antipsychotic treatment in VA patients with schizophrenia.

Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC.

Schizophr Res. 2006 May;84(1):90-9. Epub 2006 May 2.

PMID:
16631354
[PubMed - indexed for MEDLINE]
3.

Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.

Mohamed S, Leslie DL, Rosenheck RA.

J Clin Psychiatry. 2009 Jun;70(6):906-12. doi: 10.4088/JCP.08m04450. Epub 2009 May 5.

PMID:
19422760
[PubMed - indexed for MEDLINE]
4.

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.

Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR.

Psychiatr Serv. 2007 Apr;58(4):482-8.

PMID:
17412849
[PubMed - indexed for MEDLINE]
5.
6.

Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia.

Gören JL, Meterko M, Williams S, Young GJ, Baker E, Chou CH, Kilbourne AM, Bauer MS.

Psychiatr Serv. 2013 Jun;64(6):527-33. doi: 10.1176/appi.ps.002022012.

PMID:
23450334
[PubMed - indexed for MEDLINE]
7.

National trends in psychotropic medication polypharmacy in office-based psychiatry.

Mojtabai R, Olfson M.

Arch Gen Psychiatry. 2010 Jan;67(1):26-36. doi: 10.1001/archgenpsychiatry.2009.175.

PMID:
20048220
[PubMed - indexed for MEDLINE]
8.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
[PubMed - indexed for MEDLINE]
9.

Patient characteristics and the likelihood of initiation on olanzapine or risperidone among patients with schizophrenia.

Ren XS, Kazis LE, Lee AF, Huang YH, Hamed A, Cunningham F, Herz L, Miller DR.

Schizophr Res. 2005 Sep 15;77(2-3):167-77.

PMID:
15894460
[PubMed - indexed for MEDLINE]
10.

Adherence assessments and the use of depot antipsychotics in patients with schizophrenia.

Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S.

J Clin Psychiatry. 2001 Jul;62(7):545-51.

PMID:
11488366
[PubMed - indexed for MEDLINE]
11.

Using a pharmacy-based intervention to improve antipsychotic adherence among patients with serious mental illness.

Valenstein M, Kavanagh J, Lee T, Reilly P, Dalack GW, Grabowski J, Smelson D, Ronis DL, Ganoczy D, Woltmann E, Metreger T, Wolschon P, Jensen A, Poddig B, Blow FC.

Schizophr Bull. 2011 Jul;37(4):727-36. doi: 10.1093/schbul/sbp121. Epub 2009 Nov 21.

PMID:
19933540
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The effects of race and criminal justice involvement on access to atypical antipsychotic medications among persons with schizophrenia.

Van Dorn RA, Swanson JW, Swartz MS, Elbogen EB.

Ment Health Serv Res. 2005 Jun;7(2):123-34.

PMID:
15974158
[PubMed - indexed for MEDLINE]
13.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
[PubMed - indexed for MEDLINE]
14.

Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders.

Janssen B, Gaebel W, Haerter M, Komaharadi F, Lindel B, Weinmann S.

Psychopharmacology (Berl). 2006 Aug;187(2):229-36. Epub 2006 May 19.

PMID:
16710714
[PubMed - indexed for MEDLINE]
15.

Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment.

Längle G, Steinert T, Weiser P, Schepp W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R.

Acta Psychiatr Scand. 2012 May;125(5):372-81. doi: 10.1111/j.1600-0447.2012.01835.x. Epub 2012 Feb 9.

PMID:
22321029
[PubMed - indexed for MEDLINE]
16.

Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.

Clark RE, Bartels SJ, Mellman TA, Peacock WJ.

Schizophr Bull. 2002;28(1):75-84.

PMID:
12047024
[PubMed - indexed for MEDLINE]
Free Article
17.

Benchmarking the quality of schizophrenia pharmacotherapy: a comparison of the Department of Veterans Affairs and the private sector.

Leslie DL, Rosenheck RA.

J Ment Health Policy Econ. 2003 Sep;6(3):113-21.

PMID:
14646004
[PubMed - indexed for MEDLINE]
18.

Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study.

Chakos M, Patel JK, Rosenheck R, Glick ID, Hammer MB, Tapp A, Miller A, Miller D.

Clin Schizophr Relat Psychoses. 2011 Oct;5(3):124-34. doi: 10.3371/CSRP.5.3.2. Erratum in: Clin Schizophr Relat Psychoses. 2012 Jan;5(4):184. Miller, Del [added].

PMID:
21983496
[PubMed - indexed for MEDLINE]
19.

Differential medication adherence among patients with schizophrenia and comorbid diabetes and hypertension.

Piette JD, Heisler M, Ganoczy D, McCarthy JF, Valenstein M.

Psychiatr Serv. 2007 Feb;58(2):207-12.

PMID:
17287377
[PubMed - indexed for MEDLINE]
20.

Impact of medical comorbidity on the quality of schizophrenia pharmacotherapy in a national VA sample.

Chwastiak L, Rosenheck R, Leslie D.

Med Care. 2006 Jan;44(1):55-61.

PMID:
16365613
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk